EGFR TKI-resistant NSCLC cell lines A549 and Calu6 (in combination with erlotinib).  Minor effect in H1993 cells  50–100 μM.  Improved effect with erlotinib 5 μM, with a pitavastatin dosage of 1–50 μM (Calu6) and 1–10 μM (A549). This evidence concerns the gene EGFR and non-small cell lung carcinoma.